Cargando…

The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands

INTRODUCTION: There is little information as to what extent adverse drug reactions (ADRs) influence patients’ health-related quality of life (HR-QOL). From a pharmacovigilance perspective, capturing and making the best use of this information remains a challenge. The Netherlands Pharmacovigilance Ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolfes, Leàn, van Hunsel, Florence, Taxis, Katja, van Puijenbroek, Eugène
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933735/
https://www.ncbi.nlm.nih.gov/pubmed/27145946
http://dx.doi.org/10.1007/s40264-016-0422-0
_version_ 1782441217683881984
author Rolfes, Leàn
van Hunsel, Florence
Taxis, Katja
van Puijenbroek, Eugène
author_facet Rolfes, Leàn
van Hunsel, Florence
Taxis, Katja
van Puijenbroek, Eugène
author_sort Rolfes, Leàn
collection PubMed
description INTRODUCTION: There is little information as to what extent adverse drug reactions (ADRs) influence patients’ health-related quality of life (HR-QOL). From a pharmacovigilance perspective, capturing and making the best use of this information remains a challenge. The Netherlands Pharmacovigilance Centre Lareb received about 1800 reports after the packaging of the drug Thyrax(®) (levothyroxine; Aspen Pharma Trading Limited, Dublin, Ireland) changed from a brown glass bottle to a blister package in the Netherlands. OBJECTIVE: The objective of this study was to explore the impact of ADRs on HR-QOL in patients who reported a possible ADR to Lareb in relation to the change in the packaging of the drug Thyrax(®). A secondary objective was to explore factors correlated with change in HR-QOL. METHODS: Patients who reported an ADR in relation to the Thyrax(®) packaging change were included in this study. A web-based adapted version of the COOP/WONCA questionnaire was sent to explore the HR-QOL before versus during the ADR, expressed on a 5-point scale from no impact (1) to high impact (5). Multivariable linear regression analysis was used to identify factors correlated with change in HR-QOL. RESULTS: Overall, 1167 patients returned the questionnaire (71.2 % response rate). The difference in HR-QOL was −0.8 for physical, −1.2 for mental, −1.4 for daily activities, −1.3 for social, and −1.3 for overall health status (p < 0.001 for each domain). Age, sex, educational level of the patient, and absence from work due to an ADR were correlated with at least one domain, while severity of the ADR was found to be correlated with all domains of HR-QOL. CONCLUSION: Patients who reported possible ADRs after the Thyrax(®) packaging change experienced a significant decrease in HR-QOL. This impact was highest for the domains ‘daily activities’, ‘overall health status’, and ‘mental health’ and lowest for ‘physical fitness’. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0422-0) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4933735
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-49337352016-07-18 The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands Rolfes, Leàn van Hunsel, Florence Taxis, Katja van Puijenbroek, Eugène Drug Saf Original Research Article INTRODUCTION: There is little information as to what extent adverse drug reactions (ADRs) influence patients’ health-related quality of life (HR-QOL). From a pharmacovigilance perspective, capturing and making the best use of this information remains a challenge. The Netherlands Pharmacovigilance Centre Lareb received about 1800 reports after the packaging of the drug Thyrax(®) (levothyroxine; Aspen Pharma Trading Limited, Dublin, Ireland) changed from a brown glass bottle to a blister package in the Netherlands. OBJECTIVE: The objective of this study was to explore the impact of ADRs on HR-QOL in patients who reported a possible ADR to Lareb in relation to the change in the packaging of the drug Thyrax(®). A secondary objective was to explore factors correlated with change in HR-QOL. METHODS: Patients who reported an ADR in relation to the Thyrax(®) packaging change were included in this study. A web-based adapted version of the COOP/WONCA questionnaire was sent to explore the HR-QOL before versus during the ADR, expressed on a 5-point scale from no impact (1) to high impact (5). Multivariable linear regression analysis was used to identify factors correlated with change in HR-QOL. RESULTS: Overall, 1167 patients returned the questionnaire (71.2 % response rate). The difference in HR-QOL was −0.8 for physical, −1.2 for mental, −1.4 for daily activities, −1.3 for social, and −1.3 for overall health status (p < 0.001 for each domain). Age, sex, educational level of the patient, and absence from work due to an ADR were correlated with at least one domain, while severity of the ADR was found to be correlated with all domains of HR-QOL. CONCLUSION: Patients who reported possible ADRs after the Thyrax(®) packaging change experienced a significant decrease in HR-QOL. This impact was highest for the domains ‘daily activities’, ‘overall health status’, and ‘mental health’ and lowest for ‘physical fitness’. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s40264-016-0422-0) contains supplementary material, which is available to authorized users. Springer International Publishing 2016-05-04 2016 /pmc/articles/PMC4933735/ /pubmed/27145946 http://dx.doi.org/10.1007/s40264-016-0422-0 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Rolfes, Leàn
van Hunsel, Florence
Taxis, Katja
van Puijenbroek, Eugène
The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
title The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
title_full The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
title_fullStr The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
title_full_unstemmed The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
title_short The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
title_sort impact of experiencing adverse drug reactions on the patient’s quality of life: a retrospective cross-sectional study in the netherlands
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933735/
https://www.ncbi.nlm.nih.gov/pubmed/27145946
http://dx.doi.org/10.1007/s40264-016-0422-0
work_keys_str_mv AT rolfeslean theimpactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT vanhunselflorence theimpactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT taxiskatja theimpactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT vanpuijenbroekeugene theimpactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT rolfeslean impactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT vanhunselflorence impactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT taxiskatja impactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands
AT vanpuijenbroekeugene impactofexperiencingadversedrugreactionsonthepatientsqualityoflifearetrospectivecrosssectionalstudyinthenetherlands